AR031924A1 - Anticuerpos anti-cd28 silenciados y el uso de estos - Google Patents

Anticuerpos anti-cd28 silenciados y el uso de estos

Info

Publication number
AR031924A1
AR031924A1 ARP010105828A ARP010105828A AR031924A1 AR 031924 A1 AR031924 A1 AR 031924A1 AR P010105828 A ARP010105828 A AR P010105828A AR P010105828 A ARP010105828 A AR P010105828A AR 031924 A1 AR031924 A1 AR 031924A1
Authority
AR
Argentina
Prior art keywords
antibodies
silenced
methods
tissues
defective
Prior art date
Application number
ARP010105828A
Other languages
English (en)
Spanish (es)
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of AR031924A1 publication Critical patent/AR031924A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP010105828A 2000-12-14 2001-12-14 Anticuerpos anti-cd28 silenciados y el uso de estos AR031924A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14

Publications (1)

Publication Number Publication Date
AR031924A1 true AR031924A1 (es) 2003-10-08

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105828A AR031924A1 (es) 2000-12-14 2001-12-14 Anticuerpos anti-cd28 silenciados y el uso de estos

Country Status (18)

Country Link
EP (1) EP1341553A4 (no)
JP (1) JP2004515243A (no)
KR (1) KR20040020866A (no)
CN (1) CN1272345C (no)
AR (1) AR031924A1 (no)
AU (2) AU2608602A (no)
BR (1) BR0116686A (no)
CA (1) CA2432736A1 (no)
CZ (1) CZ20031909A3 (no)
HU (1) HUP0400697A3 (no)
IL (1) IL156262A0 (no)
MX (1) MXPA03005327A (no)
NO (1) NO20032542L (no)
NZ (1) NZ526569A (no)
PL (1) PL363239A1 (no)
RU (1) RU2261723C2 (no)
WO (1) WO2002047721A1 (no)
ZA (1) ZA200305384B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066059A2 (en) 2001-02-16 2002-08-29 Genetics Institute, Llc Agents that specifically block cd28-mediated signaling and uses therefor
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
FR2951176A1 (fr) * 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
ES2680570T3 (es) * 2010-02-18 2018-09-10 Ose Immunotherapeutics Anticuerpos humanizados anti-CD28
EP3528787A4 (en) 2016-10-21 2020-05-06 Amgen Inc. PHARMACEUTICAL FORMULATIONS AND PROCESSES FOR THEIR PREPARATION
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US20220153845A1 (en) * 2019-03-14 2022-05-19 Biond Biologics Ltd. A method for immunosuppression
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein

Also Published As

Publication number Publication date
HUP0400697A3 (en) 2007-05-02
IL156262A0 (en) 2004-01-04
EP1341553A4 (en) 2004-07-28
NZ526569A (en) 2005-07-29
CN1489473A (zh) 2004-04-14
NO20032542D0 (no) 2003-06-05
NO20032542L (no) 2003-08-07
KR20040020866A (ko) 2004-03-09
RU2261723C2 (ru) 2005-10-10
ZA200305384B (en) 2004-10-11
AU2002226086C1 (en) 2006-03-09
CA2432736A1 (en) 2002-06-20
RU2003121231A (ru) 2005-02-10
HUP0400697A2 (hu) 2004-06-28
BR0116686A (pt) 2003-12-30
WO2002047721A1 (en) 2002-06-20
PL363239A1 (en) 2004-11-15
JP2004515243A (ja) 2004-05-27
MXPA03005327A (es) 2004-12-03
CN1272345C (zh) 2006-08-30
CZ20031909A3 (cs) 2003-11-12
AU2608602A (en) 2002-06-24
AU2002226086B2 (en) 2005-08-25
EP1341553A1 (en) 2003-09-10

Similar Documents

Publication Publication Date Title
AR031924A1 (es) Anticuerpos anti-cd28 silenciados y el uso de estos
MX2009003588A (es) Composiciones de colageno placentario (telopeptido), natural.
ES2183937T3 (es) Inhibidores de la adhesion celular.
UY24256A1 (es) Anticuerpos monoclonales de mono especificos para anticuerpos humanos b 7.1 y/o b7.2, formas primatizadas de los mis- mos, composiciones farmaceuticas que los contienen y uso de los mismos como inmunosupresores
BR0114630A (pt) Secretagogos de hormÈnio do crescimento
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
ATE529125T1 (de) Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung
GT200300031A (es) Indazoles substitutos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
CY1109413T1 (el) Μεθοδοι θεραπειας πολλαπλου μυελωματος και διεγειρομενης απο μυελωμα επαναρροφησης οστου χρησιμοποιωντας ανταγωνιστες συνδεσης ιντεγκρινης/υποδοχεα
BR0214029A (pt) Métodos e composições para o uso de células estromais para suportar células tronco embriÈnicas e adultas
BR0210593A (pt) polinucleotìdeos de defensina e métodos de uso
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
AR023463A1 (es) Uso de compuestos de azetidinona
BRPI0607883A2 (pt) método para obter material celular prontamente disponìvel derivado de sangue periférico e uma composição do referido material celular
ECSP045146A (es) Moléculas pequeñas para el tratamiento del crecimiento celular anormal
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
BRPI0607504A2 (pt) população de suìnos que possui baixos nìveis de retrovìrus endógenos suìnos e usos dos mesmos
BR0307629A (pt) Métodos e composições para tratar condições hiperproliferativas
GT200300046A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
HK1205531A1 (en) Mesenchymal stem cells and uses therefor
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
DE69721021D1 (de) Blasenmukosa mit zellen für die rekonstruktion von geweben
ES2061863T3 (es) Nuevas quinoliloxazol-2-onas utiles como inhibidores de proteina quinasa c.
WO2007002469A3 (en) Therapeutic compositions and methods using transforming growth factor-beta mimics

Legal Events

Date Code Title Description
FB Suspension of granting procedure